GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

PAHC · Jun 30, 2024

PHIBRO ANIMAL HEALTH CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001558370-24-012517General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

30.67% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

4.05% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

8.61% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

4.07% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

26.13% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

30.77% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

5.24% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

2.87% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

0.05% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History12 statesHistory building

Jun 30, 20230/7 normalizedLevel 3 Sep 30, 20230/7 normalizedLevel 3 Dec 31, 20230/7 normalizedLevel 3 Mar 31, 20240/6 normalizedLevel 3 Jun 30, 20240/9 normalizedLevel 3 Sep 30, 20240/8 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20255/8 normalizedLevel 3 Sep 30, 20256/8 normalizedLevel 3 Dec 31, 20257/8 normalizedLevel 3 Mar 31, 20267/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 3.70%
Current: 4.05%
Delta: 0.36%

Cash Generation Increased

Previous: 4.33%
Current: 8.61%
Delta: 4.27%

Inventory Pressure Decreased

Previous: 107.24%
Current: 26.13%
Delta: -81.11%

Margin Increased

Previous: 30.24%
Current: 30.77%
Delta: 0.52%

Profitability Decreased

Previous: 7.57%
Current: 5.24%
Delta: -2.33%

Sbc Intensity Decreased

Previous: 0.05%
Current: 0.05%
Delta: -0.00%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · PAHC Fundamental State →Has State · PHIBRO ANIMAL HEALTH CORP →Transitioned To · PAHC Fundamental State →Transitioned To · PAHC CAPEX_INTENSITY_INCREASED →Transitioned To · PAHC CASH_GENERATION_INCREASED →Transitioned To · PAHC INVENTORY_PRESSURE_DECREASED →Transitioned To · PAHC MARGIN_INCREASED →Transitioned To · PAHC PROFITABILITY_DECREASED →Transitioned To · PAHC SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.